Search
forLearn
5 / 801 resultslearn L-cysteine
learn acetyl cysteine
learn Ensete ventricosum
learn Isostearamidopropyl
Research
5 / 1000+ results
research Cutaneous Adnexal Cysts Revisited: What We Know and What We Think We Know
A new classification system for skin cysts was proposed to improve diagnosis.
research Ultrastructural characteristics of trichilemmal cysts: report of two cases
Trichilemmal cysts may form from hair follicle outer root sheath growth.
research Quisto matrical. Diagnósticos diferenciais.
The skin lesion was diagnosed as a matrical cyst with unusual features.
research Baker′s dozen on the scalp: An interesting case of multiple trichilemmal cyst
A woman had 13 non-cancerous cysts on her scalp successfully removed in one surgery.
research Cutaneous Hybrid Cyst in a Sprague-Dawley Rat
A rat had a cyst similar to a hair follicle structure.
Community Join
5 / 1000+ resultscommunity Progress but at different times?
The user has been taking 1.25mg of oral minoxidil and 1mg of finasteride for a year and added topical minoxidil in January. They noticed hair improvement but are experiencing uneven regrowth, with the hairline improving and the middle part worsening.
community The MPB itch aka DHT itch is very real.
Hair loss itch is caused by DHT attacking follicles and stimulating nerves. Finasteride users who respond well don't experience this itch.
community Microneedling depth. Does one length fit all areas of the scalp? Maybe not.
Microneedling depth should be customized based on hair type and scalp area, with many users finding 0.5-0.6mm effective for miniaturized hairs to avoid damage. Users report varying pain levels and results, with some preferring shorter needle lengths and others using longer ones like 1.75mm for scalp health and density improvement.
community Microneedling must reach the stem cells in the upper hair shaft
Microneedling should target depths of 0.5mm to 1.5mm for hair loss, with weekly sessions at 1mm recommended. Combining microneedling with Minoxidil is common for improved results.
community Quote from Pelage (PP-405) Spokesperson...
Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.